Neurocrine Biosciences Inc

NASDAQ:NBIXUnited States

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Contact Information

Headquarters

6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130

Phone

858-617-7600

Fax

858-617-7602

Executives

Non-Executive Independent Chairman of the Board

William Rastetter

Chief Executive Officer, Director

Kevin Gorman

Chief Financial Officer

Matthew Abernethy

Chief Human Resource Officer

Julie Cooke

Chief Scientific Officer

Jude Onyia